Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD

ConclusionsData from the extension phase of the CONFIDENCE study show that the benefits associated with GA40 treatment in terms of medication satisfaction, treatment convenience perception, symptomatic changes in fatigue impact and mental health status, and treatment adherence were maintained over a 12-month observation period. These results confirm the preferential utility of GA40 versus GA20 in clinical practice, with no additional safety concerns associated with switching from GA20 to GA40.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 8 April 2020Source: NeuroImageAuthor(s): Dinesh K. Sivakolundu, Kathryn L. West, Mark Zuppichini, Monroe P. Turner, Dema Abdelkarim, Yuguang Zhao, Jeffrey S. Spence, Hanzhang Lu, Darin T. Okuda, Bart Rypma
Source: NeuroImage - Category: Neuroscience Source Type: research
Objectives The aim of the study was to implement a deep-learning tool to produce synthetic double inversion recovery (synthDIR) images and compare their diagnostic performance to conventional sequences in patients with multiple sclerosis (MS). Materials and Methods For this retrospective analysis, 100 MS patients (65 female, 37 [22–68] years) were randomly selected from a prospective observational cohort between 2014 and 2016. In a subset of 50 patients, an artificial neural network (DiamondGAN) was trained to generate a synthetic DIR (synthDIR) from standard acquisitions (T1, T2, and fluid-attenuated inversion ...
Source: Investigative Radiology - Category: Radiology Tags: Original Articles Source Type: research
No abstract available
Source: Investigative Radiology - Category: Radiology Tags: Editorial Source Type: research
Condition:   Relapsing Multiple Sclerosis Interventions:   Drug: Evobrutinib;   Drug: Placebo (match to Teriflunomide);   Drug: Teriflunomide;   Drug: Placebo (match to Evobrutinib) Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   EMD Serono Research & Development Institute, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsing Multiple Sclerosis Interventions:   Drug: Evobrutinib;   Drug: Placebo (match to Teriflunomide);   Drug: Teriflunomide;   Drug: Placebo (match to Evobrutinib) Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   EMD Serono Research & Development Institute, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Fall;   Multiple Sclerosis;   Lower Urinary Tract Symptoms Intervention:   Other: Clinical tests Sponsor:   Gérard Amarenco Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsing Multiple Sclerosis Interventions:   Drug: Evobrutinib;   Drug: Placebo (match to Teriflunomide);   Drug: Teriflunomide;   Drug: Placebo (match to Evobrutinib) Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   EMD Serono Research & Development Institute, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsing Multiple Sclerosis Interventions:   Drug: Evobrutinib;   Drug: Placebo (match to Teriflunomide);   Drug: Teriflunomide;   Drug: Placebo (match to Evobrutinib) Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   EMD Serono Research & Development Institute, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Fall;   Multiple Sclerosis;   Lower Urinary Tract Symptoms Intervention:   Other: Clinical tests Sponsor:   Gérard Amarenco Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: The endoscopic injection of onaBTA marked by MB into the bladder wall is associated with minimal intravesical loss of the agent, representing less than 3% of the administered dose of MB. This may reflect the amount of the onaBTA detected in the irrigation fluid. PMID: 32252187 [PubMed]
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
More News: Copaxone | Men | Multiple Sclerosis | Neurology | Study